Finance

Lists
Q3 2026 earnings • released • EPS beat +26.73%
See results
KLRA:NASDAQ
Kailera Therapeutics Inc
$12.97
+6.57%
(+0.80) 1D
$13.31
+2.62% (+0.34)
After hours
Closed: Nov 6, 4:00:01 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for KLRA...
Open
$12.29
High
$13.26
Low
$11.96
Mkt. cap
1.68B
Avg. vol.
1.21M
Volume
733.27K
52-wk high
$28.23
52-wk low
$9.76
No. of employees
145
Open
$12.29
High
$13.26
Low
$11.96
Mkt. cap
1.68B
Avg. vol.
1.21M
Volume
733.27K
52-wk high
$28.23
52-wk low
$9.76
No. of employees
145
News stories
From web sources and news partners
About Kailera Therapeutics Inc
CEO-
Employees145
Founded2024
HeadquartersWaltham, Massachusetts, United States
SectorHealth Care
IndustryBiotechnology
Websitekailera.com
Analyst ratings
Based on 5 analysts giving stock ratings to KLRA in the past 3 months
Strong buy
Buy
5
Hold
0
Sell
0
12-month forecast
Based on 5 Wall Street analysts offering 12 month price targets for KLRA in the last 3 months.
Highest
Current $12.97
$57.00 (+339.48%)
Average
$42.75 (+229.61%)
Lowest
$30.00 (+131.30%)
Analyst
Recommendation
Action
Price target
Projected
Date
Unknown Analyst
Leerink Partners
Buy
Maintained
$36.00
+177.6%
11/05/2026
Andy Hsieh
William Blair
Buy
Maintained
-
-
09/30/2026
Yaron Werber
TD Cowen
Buy
Maintained
$57.00
+339.5%
09/29/2026
Roger Song
Jefferies
Buy
Maintained
$48.00
+270.1%
08/14/2026
Hardik Parikh
J.P. Morgan
Buy
Maintained
$30.00
+131.3%
08/12/2026
Umer Raffat
Evercore ISI
Buy
Initiated
-
-
05/12/2026
Last report
Nov 4, 2026
Fiscal period
Q3 2026
-$0.74 / -$1.01
+26.73%beat
Revenue / Est. (USD)
- / 0.00
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
26.99M
70.87M
101.06M
84.67M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
13.12M
13.79M
20.31M
21.67M
Operating expense
40.11M
84.66M
121.37M
106.34M
Total operating expenses
40.11M
84.66M
121.37M
106.34M
Operating income
-40.11M
-84.66M
-121.37M
-106.34M
Other non operating income
-1.76M
79.00K
72.00K
60.00K
EBT including unusual items
-39.62M
-78.86M
-111.31M
-95.66M
EBT excluding unusual items
-39.62M
-78.86M
-111.31M
-95.66M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-39.62M
-78.86M
-111.31M
-95.66M
Net profit margin
-
-
-
-
Earnings per share
-
-3.65
-1.09
-0.74
Interest and investment income
2.25M
5.72M
9.99M
10.61M
Interest expense
-
-
-
-
Net interest expenses
2.25M
5.72M
9.99M
10.61M
Depreciation and amortization charges
-
-
-
-
EBITDA
-40.05M
-84.56M
-121.27M
-106.24M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps